Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K
Drug Discovery: Overview01:26

Drug Discovery: Overview

11.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.1K
Pharmacovigilance01:19

Pharmacovigilance

1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

231
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
231
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

311
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
311
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient selection refines total hip arthroplasty free survival after hip arthroscopy: an eighteen year, one thousand and fifty one hip cohort study.

International orthopaedics·2026
Same author

Rate of functional recovery after hip arthroscopy for femoroacetabular impingement syndrome: patient-reported outcomes at three, six, and twelve months.

International orthopaedics·2026
Same author

Intelligent tool orchestration for rapid mechanistic model prototyping: MCP servers as AI-biology interfaces.

NPJ systems biology and applications·2026
Same author

Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures".

ACS pharmacology & translational science·2026
Same author

Leveraging training expertise to build capacity in computational personalised medicine.

Bioinformatics advances·2026
Same author

Correction to "SH2<i>scan</i>: Mapping SH2 Domain-Ligand Binding Selectivity for Inhibitors and Degraders".

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Jan 17, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K

Comprehensive Analysis of Clinically Discontinued Compounds Using an In Vitro Secondary Pharmacology Panel to Predict

Verena Albert1, Danielle E Skinner1, Saloni Karnwal1

  • 1Eurofins DiscoverX, LLC, 11180 Roselle Street, Suite D, San Diego, California 92121, United States of America.

ACS Pharmacology & Translational Science
|September 19, 2025
PubMed
Summary

In vitro secondary pharmacology screens potential drug liabilities early. This safety pharmacology approach using platforms like SAFETYscan47 helps reduce clinical trial failures and improve patient safety.

Keywords:
NAMadverse drug eventscell-based assaypreclinicalsafety pharmacologysecondary pharmacology

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.2K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.6K

Related Experiment Videos

Last Updated: Jan 17, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.2K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.6K

Area of Science:

  • Pharmacology
  • Drug Discovery
  • Toxicology

Background:

  • In vitro secondary pharmacology is crucial for identifying off-target interactions in drug discovery.
  • Early evaluation of potential liabilities reduces clinical attrition and enhances patient safety.
  • Safety pharmacological profiling is a standard approach for lead candidates.

Purpose of the Study:

  • To highlight the utility of in vitro pharmacological profiling in preclinical drug discovery.
  • To demonstrate how evaluating data from platforms like SAFETYscan47 can mitigate risks.
  • To support patient safety and reduce clinical attrition by improving early compound assessment.

Main Methods:

  • Utilizing a high-throughput screening platform (SAFETYscan47) for broad target profiling.
  • Analyzing in vitro secondary pharmacology data of discovery compounds.
  • Comparing clinically failed drug candidates with a broader compound dataset.

Main Results:

  • High-throughput screening enables rapid identification of potential liabilities in compounds.
  • In vitro profiling provides valuable insights into compound safety during preclinical stages.
  • Analysis of failed candidates informs the mitigation of risks in new drug discovery.

Conclusions:

  • In vitro secondary pharmacology is essential for reducing clinical attrition.
  • Platforms like SAFETYscan47 facilitate early detection and mitigation of drug liabilities.
  • Robust preclinical safety profiling ultimately supports patient safety and successful drug development.